Rosacea Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, NDA Approvals, Medication, Prevalence, MOA, Revenue, Statistics and Companies by DelveInsight
"Rosacea Treatment Market"
Rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
(Albany, USA) DelveInsight's ' Rosacea Market Insights, Epidemiology, and Market Forecast-2034 ' report offers an in-depth understanding of Rosacea, including historical and forecasted epidemiology, as well as Rosacea market trends in the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
The latest healthcare forecast report delivers a comprehensive analysis of Rosacea, offering critical insights into prevalence, revenue trends, and evolving Rosacea treatment options. The report discusses key statistics, including current and projected market sizes, while also delving into Rosacea symptoms and their impact on patients' quality of life.
It evaluates the progress and effectiveness of emerging therapies for Rosacea alongside an in-depth examination of the clinical trial landscape. This includes a detailed review of ongoing and upcoming studies that are set to shape the future of Rosacea treatment. With its rich data and forward-looking insights, this report serves as an indispensable resource for understanding market dynamics and advancements in the field of Rosacea.
Some of the key insights of Rosacea Market Report:
The rosacea market size is expected to experience significant growth during the forecast period (2024–2034). This growth is a direct consequence of various market-driving factors such as improving access to diagnosis and treatment, increased awareness and research, advancements in treatment options, and increasing prevalence of rosacea.
Emerging therapies for rosacea include AIV001, TP-04, B244, and others.
Key rosacea companies in the treatment market include Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
In the US, the prevalence of rosacea is increasing, with around 16 million Americans affected, according to the American Academy of Dermatology.
In the UK, rosacea affects approximately 2 per 1,000 persons, with prevalence rates ranging from 0.10% to 22%.
In Germany, the prevalence of rosacea was around 12%, with erythematotelangiectatic (ETR) and papulopustular (PPR) subtypes accounting for 9% and 3%, respectively. About 18% of diagnosed cases were in individuals aged 18-30 years.
Rosacea is more common in females, with nearly 90% of cases in women compared to 15% in men. The most common subtypes were erythematotelangiectatic (60%), papulopustular (30%), phytates (20%), and ocular (40%).
The rosacea treatment market is currently led by EPSOLAY, a product by Sol-Gel Technologies and Galderma, which is expected to expand in the coming years.
On November 5, 2024, the FDA approved minocycline hydrochloride extended-release capsules (DFD-29, Emrosi) for treating inflammatory lesions caused by rosacea in adults. This approval followed positive Phase 3 trial results.
Rosacea Overview:
Rosacea is a chronic skin condition characterized by facial erythema (redness) that affects around 1 in 10 people worldwide. Rosacea symptoms vary widely, with some individuals experiencing persistent redness, visible blood vessels, and swollen, red bumps that resemble acne. The condition can be categorized into four types: erythematotelangiectatic rosacea, papulopustular rosacea (PPR), phymatous rosacea, and ocular rosacea. Many patients exhibit symptoms of more than one type, making diagnosis and treatment more complex.
Papulopustular rosacea, also known as inflammatory rosacea or type-2 rosacea, is commonly mistaken for acne due to the presence of 'whitehead' pustules and red, swollen bumps, particularly on the cheeks, chin, and forehead. This subtype of rosacea often flares up for weeks to months before subsiding temporarily. While the exact causes remain unclear, researchers suggest that genetic predisposition, immune responses to Bacillus oleronius and H. pylori infections, overproduction of cathelicidin protein, or Demodex mites living on the skin may play a role in its development.
The diagnosis of rosacea is largely based on patient history and physical examination. However, its symptoms can be confused with other skin conditions such as adult acne vulgaris, photodermatitis, seborrheic dermatitis, or contact dermatitis. This overlap of rosacea symptoms highlights the need for careful evaluation to ensure accurate diagnosis and treatment.
The therapeutic landscape of rosacea includes various drug classes used to treat rosacea, with treatments tailored based on the severity and subtype of the condition. The primary options include topical retinoids, topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids. For moderate cases of papulopustular rosacea, combination therapy with oral tetracyclines and topical agents is the first-line choice. Maintenance therapy often involves topical agents like metronidazole. Among topical treatments, retinoids such as tretinoin, tazarotene, and adapalene are commonly prescribed to reduce erythema, papules, pustules, and telangiectasia.
Tretinoin, one of the most affordable and widely used topical retinoids, is often the drug of choice for treating rosacea symptoms. Topical antibiotics, including metronidazole, clindamycin, erythromycin, azelaic acid, benzoyl peroxide, and sulfacetamide, are also applied to the skin to combat surface bacteria and reduce inflammation. Among the new drugs for rosacea, EPSOLAY is the only US FDA-approved topical treatment for rosacea, highlighting the growing focus on targeted therapies to address unmet needs in this space.
With ongoing advancements, researchers continue to explore innovative drugs to treat rosacea, offering hope for improved management strategies and better quality of life for patients.
Rosacea Epidemiology:
The epidemiology section offers an overview of historical, current, and projected trends in the seven major countries (7MM) from 2020 to 2034. It helps identify the factors influencing these trends by examining various studies and perspectives from key opinion leaders. Additionally, the section provides an in-depth analysis of the diagnosed patient population and future trends.
The Rosacea market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total prevalent cases of rosacea
Diagnosed prevalent cases of rosacea
Type-specific diagnosed prevalent cases of rosacea
Treated cases of rosacea
Download the report to understand which factors are driving Rosacea epidemiology trends @ Rosacea Epidemiology Forecast
Rosacea Drugs Uptake and Pipeline Development Activities:
The drug uptake section examines the adoption rates of newly launched and upcoming Rosacea drugs over the study period. It analyzes the uptake of these treatments, evaluating how patients adopt these therapies and the sales performance of each drug. This section offers a comprehensive look at the factors influencing the acceptance and success of Rosacea treatments in the market.
In addition, the therapeutics assessment section highlights the Rosacea drugs that have experienced the fastest uptake. It delves into the key drivers behind their widespread use and provides a market share comparison among these drugs. This section helps identify which therapies are gaining traction and the reasons behind their rapid adoption.
The report further explores the Rosacea pipeline, providing insights into therapeutic candidates at different stages of development. It identifies the key companies involved in creating targeted Rosacea treatments. The report also covers recent developments in the field, including collaborations, mergers, acquisitions, licensing agreements, and other significant updates on emerging therapies for Rosacea.
Rosacea Market Outlook:
The Rosacea market is poised for significant changes and growth in the coming years, driven by ongoing research and development efforts to address unmet medical needs. Current treatment options for rosacea, particularly for papulopustular rosacea, include approved and off-label therapies belonging to therapeutic categories, such as topical antibiotics, oral tetracycline-class antibiotics (TCAs), and oral retinoids.
Topical antibiotics, the most commonly prescribed class of rosacea for all sexes and age groups, include metronidazole, clindamycin, erythromycin, and azelaic acid, with metronidazole leading in prescription volume. Oral TCAs like tetracycline, minocycline, and doxycycline (Oracea) are effective anti-inflammatory agents, with tetracycline being the most prescribed, followed by minocycline and doxycycline. While oral retinoids, such as isotretinoin, are often used as an off-label therapy, studies suggest that low-dose isotretinoin may offer better outcomes compared to doxycycline in some instances.
Despite the availability of these therapies, there remains a significant need for novel and more effective treatments to manage rosacea symptoms and improve patient outcomes. Encouragingly, many companies are developing innovative drugs to meet these unmet needs, which is expected to drive market growth. According to DelveInsight, the rosacea market in the 7MM (US, EU5, and Japan) is projected to experience substantial growth during the study period of 2020–2034, as advancements in research and therapeutic innovation continue to shape the market landscape.
To learn more about Rosacea therapies and Compsnies working in the treatment market, visit @ Rosacea Medication and Pipeline
Rosacea Market Drivers:
The increasing prevalence of rosacea, driven by factors like environmental changes and lifestyle, is pushing the demand for treatments.
Ongoing research and introducing new, more effective medications are encouraging growth in the rosacea market.
Rosacea Market Barriers:
The absence of a permanent cure for rosacea can lead to long-term patient frustration, affecting market confidence.
The stigma surrounding visible skin conditions may discourage people from seeking treatment, limiting market potential.
Scope of the Rosacea Market Report:
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Rosacea Companies: Sol-Gel Technologies, Galderma, Tarsus Pharmaceuticals, AiViva Biopharma, AOBiome, and others.
Key Rosacea Therapies: AIV001, TP-04, B244, and others.
Rosacea Therapeutic Assessment: Rosacea currently marketed, and Rosacea emerging therapies
Rosacea Market Dynamics: Rosacea market drivers and Rosacea market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Rosacea Unmet Needs, KOL's views, Analyst's views, Rosacea Market Access and Reimbursement
To learn more about Rosacea companies working in the treatment market, visit @ Rosacea Clinical Trials and Therapeutic Assessment
Table of Contents:
1. Rosacea Market Report Introduction
2. Executive Summary for Rosacea
3. SWOT analysis of Rosacea
4. Rosacea Patient Share (%) Overview at a Glance
5. Rosacea Market Overview at a Glance
6. Rosacea Disease Background and Overview
7. Rosacea Epidemiology and Patient Population
8. Country-Specific Patient Population of Rosacea
9. Rosacea Current Treatment and Medical Practices
10. Rosacea Unmet Needs
11. Rosacea Emerging Therapies
12. Rosacea Market Outlook
13. Country-Wise Rosacea Market Analysis (2020–2034)
14. Rosacea Market Access and Reimbursement of Therapies
15. Rosacea Market Drivers
16. Rosacea Market Barriers
17. Rosacea Appendix
18. Rosacea Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight:
DelveInsight is a premier healthcare business consultant and market research firm, specializing in life sciences. We empower pharmaceutical companies with comprehensive end-to-end solutions designed to enhance performance and drive growth.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/aacr-annual-meeting
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Sun
13 hours ago
- Toronto Sun
Mike Johnson downplays Musk's influence and says Republicans will pass Trump's tax and budget bill
Published Jun 08, 2025 • 3 minute read Speaker of the House Mike Johnson, R-La., wraps up a news conference on President Donald Trump's bill of tax breaks and spending cuts, at the Capitol in Washington, Wednesday, June 4, 2025. Photo by J. Scott Applewhite / AP With an uncharacteristically feistiness, Speaker Mike Johnson took clear sides Sunday in President Donald Trump's breakup with mega-billionaire Elon Musk. The Republican House leader and staunch Trump ally said Musk's criticism of the GOP's massive tax and budget policy bill will not derail the measure, and he downplayed Musk's influence over the GOP-controlled Congress. 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' 'What we're trying to do is help hardworking Americans who are trying to provide for their families and make ends meet,' Johnson insisted. Johnson said he has exchanged text messages with Musk since the former chief of Trump's Department of Government Efficiency came out against the GOP bill. This advertisement has not loaded yet, but your article continues below. THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. SUBSCRIBE TO UNLOCK MORE ARTICLES Subscribe now to read the latest news in your city and across Canada. Unlimited online access to articles from across Canada with one account. Get exclusive access to the Toronto Sun ePaper, an electronic replica of the print edition that you can share, download and comment on. Enjoy insights and behind-the-scenes analysis from our award-winning journalists. Support local journalists and the next generation of journalists. Daily puzzles including the New York Times Crossword. REGISTER / SIGN IN TO UNLOCK MORE ARTICLES Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account. Share your thoughts and join the conversation in the comments. Enjoy additional articles per month. Get email updates from your favourite authors. THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK. Create an account or sign in to continue with your reading experience. Access articles from across Canada with one account Share your thoughts and join the conversation in the comments Enjoy additional articles per month Get email updates from your favourite authors Don't have an account? Create Account Speaker Mike Johnson on the Trump-Musk feud: 'Hopefully these two titans can reconcile. I think the president's head is in the right place … There's a lot of emotion involved in it, but it's in the interest of the country for everybody to work together.' — This Week (@ThisWeekABC) June 8, 2025 Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk. The speaker was dismissive of Musk's threats to finance opponents — even Democrats — of Republican members who back Trump's bill. 'We've got almost no calls to the offices, any Republican member of Congress,' Johnson said. 'And I think that indicates that people are taking a wait and see attitude. Some who may be convinced by some of his arguments, but the rest understand: this is a very exciting piece of legislation.' Your noon-hour look at what's happening in Toronto and beyond. By signing up you consent to receive the above newsletter from Postmedia Network Inc. Please try again This advertisement has not loaded yet, but your article continues below. Johnson argued that Musk still believes 'that our policies are better for human flourishing. They're better for the US economy. They're better for everything that he's involved in with his innovation and job creation and entrepreneurship.' RECOMMENDED VIDEO The speaker and other Republicans, including Trump's White House budget chief, continued their push back Sunday against forecasts that their tax and budget plans will add to annual deficits and thus balloon a national debt already climbing toward $40 trillion. Johnson insisted that Musk has bad information, and the speaker disputed the forecasts of the nonpartisan Congressional Budget Office that scores budget legislation. The bill would extend the 2017 Trump tax cuts, cut spending and reduce some other levies but also leave some 10.9 million more people without health insurance and spike deficits by $2.4 trillion over the decade, according to the CBO's analysis. This advertisement has not loaded yet, but your article continues below. The speaker countered with arguments Republicans have made for decades: That lower taxes and spending cuts would spur economic growth that ensure deficits fall. Annual deficits and the overall debt actually climbed during the administrations of Ronald Reagan and George W. Bush, and during Trump's first presidency, even after sweeping tax cuts. Russell Vought, who leads the White House Office of Budget and Management, said on Fox News Sunday that CBO analysts base their models of 'artificial baselines.' Because the 2017 tax law set the lower rates to expire, CBO's cost estimates, Vought argued, presuming a return to the higher rates before that law went into effect. Vought acknowledged CBO's charge from Congress is to analyze legislation and current law as it is written. But he said the office could issue additional analyses, implying it would be friendlier to GOP goals. Asked whether the White House would ask for alternative estimates, Vought again put the burden on CBO, repeating that congressional rules allow the office to publish more analysis. This advertisement has not loaded yet, but your article continues below. Read More Other Republicans, meanwhile, approached the Trump-Musk battle cautiously. 'As a former professional fighter, I learned a long time ago, don't get between two fighters,' said Oklahoma Sen. Markwayne Mullin on CNN's 'State of the Union.' He even compared the two billionaire businessmen to a married couple. 'President Trump is a friend of mine but I don't need to get, I can have friends that have disagreements,' Mullin said. 'My wife and I dearly love each other and every now and then, well actually quite often, sometimes she disagrees with me, but that doesn't mean that we can't stay focused on what's best for our family. Right now, there may be a disagreement but we're laser focused on what is best for the American people.' — Associated Press journalist Gary Fields contributed from Washington. Sports Canada Sunshine Girls World Crime
Edmonton Journal
13 hours ago
- Edmonton Journal
Trump's tax and budget bill was written for 'hardworking Americans, not 'to please' Musk: Mike Johnson
Article content 'I didn't go out to craft a piece of legislation to please the richest man in the world,' Johnson said on ABC's 'This Week.' 'What we're trying to do is help hardworking Americans who are trying to provide for their families and make ends meet,' Johnson insisted. Johnson said he has exchanged text messages with Musk since the former chief of Trump's Department of Government Efficiency came out against the GOP bill. Raymond J. de Souza: This Trump-Musk cage match could be seen coming Musk called it an 'abomination' that would add to U.S. debts and threaten economic stability. He urged voters to flood Capitol Hill with calls to vote against the measure, which is pending in the Senate after clearing the House. His criticism sparked an angry social media back-and-forth with Trump, who told reporters over the weekend that he has no desire to repair his relationship with Musk.
Global News
13 hours ago
- Global News
U.S. envoy closely eyes Canada defence spending; says NATO about collective defence
The American ambassador to Canada is closely watching as Ottawa shapes its defence budget, but says the U.S. will not dictate what the Canadian government must spend. 'We're not expecting anything; that's not our job to make those expectations,' Ambassador Pete Hoekstra said in an interview with The Canadian Press this past Friday, a day after NATO defence ministers endorsed new spending targets. Hoekstra also said the point of the NATO military alliance is to defend each other when under attack. He noted Americans haven't forgotten the 'investment and the sacrifice' Canadian troops made in Afghanistan when the U.S. invoked the NATO treaty's article on collective defence. 'They were fulfilling the commitment that they made to NATO — that when one of us is attacked we are all attacked, and we will defend each other,' Hoekstra said of Canadian soldiers. Story continues below advertisement Hoekstra was not directly commenting on U.S. President Donald Trump's statement in March that Washington would not necessarily come to the aid of countries that don't pay their fair share on defence and that Canada has been freeloading on American defence of the continent. He did acknowledge Canada's defence spending has been an 'irritant' in the relationship with the U.S. This past week, defence ministers from NATO countries met in Brussels to discuss raising the member spending target on defence to as much as five per cent of GDP. Canada has never met NATO's existing spending target of two per cent since it was established in 2006. Trump and Prime Minister Mark Carney are engaged in what both sides have characterized as 'intensive' discussions toward the new economic and security deal the two leaders agreed to work on once the Canadian election concluded in April. Get breaking National news For news impacting Canada and around the world, sign up for breaking news alerts delivered directly to you when they happen. Sign up for breaking National newsletter Sign Up By providing your email address, you have read and agree to Global News' Terms and Conditions and Privacy Policy NATO figures suggest Canada's defence spending rose from about one per cent in 2014 to 1.33 per cent in 2023. The NATO secretary-general's annual report, released in April, said Canada's defence spending would hit 1.45 per cent for 2024. In terms of absolute dollars, a Canadian Global Affairs Institute analysis last year said Canada ranks as the seventh largest spender in NATO, and the 14th largest in the world. Story continues below advertisement Carney promised during the recent election campaign to move up Canada's deadline for meeting the 2 per cent threshold from 2032 to 2030 or sooner but has not yet shown a plan for how to do that. It will require Canada to add billions of new dollars annually. The prime minister is set to join other heads of government from NATO countries for an annual summit starting June 24 in the Netherlands. They are expected to approve a new defence investment plan that defence ministers hammered out this week, which would have member nations invest 3.5 per cent of GDP on core defence spending, and 1.5 per cent on defence and security-related investment such as infrastructure and resilience. That proposal is coming amid waning American commitments and a revanchist Russia. In recent years, both Democrats and Republicans have urged Canada to boost its Arctic defence, and the previous Biden administration praised much of what Ottawa outlined in an Arctic foreign policy last year. Trump has suggested defence of the Arctic is part of his 'Golden Dome' plan for a continental missile-defence shield. On May 27, the president said he told Ottawa it would cost US$61 billion to be part of the project. Hoekstra said he hasn't seen a breakdown of the costs, but said the 'really awesome technology' is likely estimated at 'proportionally what we think the Canadian share should be.' Story continues below advertisement Defence Minister David McGuinty said Canada was reviewing its defence spending from 'top to bottom' and would have more to say about its plans soon, though the government isn't planning to table a budget until the fall. Hoekstra framed NATO as part of the wide partnership the U.S. has with Canada in security, which also includes secure energy flows and stopping illicit drugs. 'We need to do the things that will keep our citizens safe,' Hoekstra said. 'There are a lot of things that Americans and Canadians have in common, and we're looking forward to great days.' Hoekstra said Trump is trying to take the U.S. off an unsustainable trajectory, which he framed as millions of people crossing the U.S. border undocumented, spending way beyond government revenue and large trade deficits. 'The president is transforming that, because we need to,' he said. Trump's discussions with Carney will likely include the sweeping reform of border security that the Liberals tabled in Parliament last week. Hoekstra had yet to go through the legislation as of Friday. The ambassador said he's focused on win-win policies for both countries and not the prospect of Canada becoming an American state, despite Trump raising the notion as a way for Canadians to save on the cost of joining his Golden Dome project. Story continues below advertisement Former Canadian diplomat Colin Robertson has said Hoekstra is limited in how much he can diverge from Trump's comments. But he said the ambassador has great access to the president, and his public messaging likely reveals how he has been advising Trump.
